Ozempic and Wegovy linked to increased hair loss

Ozempic Wegovy hair loss semaglutide GLP‑1 study

A July 2026 study published in The BMJ examined the safety of GLP‑1 medicines such as Ozempic and Wegovy. Researchers at the University of Pennsylvania reported a statistical association between use of these semaglutide‑based drugs and higher rates of hair loss, a side effect not previously recognised.

Ozempic, containing semaglutide, is approved for type‑2 diabetes, while Wegovy, a higher‑dose formulation, is approved for obesity. Both drugs are used by millions of patients worldwide for weight management as well as diabetes control. The new finding may influence treatment decisions and patient counseling.

Entities: Ozempic · The BMJ · University of Pennsylvania · Wegovy · semaglutide

Claims

What the coverage asserts, and how well corroborated each claim is across sources.

[● 6 SOURCES] Wegovy contains semaglutide, is a higher‑dose formulation, and is approved for obesity treatment. (product information)
[● 6 SOURCES] Hair loss was not previously recognised as a side effect of Ozempic or Wegovy. (medical literature)
[● 6 SOURCES] A study published in July 2026 in The BMJ examined the safety of GLP‑1 medications including Ozempic and Wegovy. (University of Pennsylvania researchers)
[● 6 SOURCES] Millions of people worldwide use Ozempic and Wegovy. (media reports)
[● 6 SOURCES] Researchers at the University of Pennsylvania found an association between Ozempic/Wegovy use and increased hair loss. (University of Pennsylvania researchers)
[● 6 SOURCES] Ozempic contains semaglutide and is approved for treating type‑2 diabetes. (product information)